Nucleic Acid Therapeutics

Papers
(The TQCC of Nucleic Acid Therapeutics is 10. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-03-01 to 2024-03-01.)
ArticleCitations
Efficiency and Target Derepression of Anti-miR-92a: Results of a First in Human Study89
The 10th Oligonucleotide Therapy Approved: Golodirsen for Duchenne Muscular Dystrophy81
Long-Term Safety and Efficacy Data of Golodirsen in Ambulatory Patients with Duchenne Muscular Dystrophy Amenable to Exon 53 Skipping: A First-in-human, Multicenter, Two-Part, Open-Label, Phase 1/2 Tr55
Transcriptome-Wide Off-Target Effects of Steric-Blocking Oligonucleotides41
Bifunctional Aptamer–Doxorubicin Conjugate Crosses the Blood–Brain Barrier and Selectively Delivers Its Payload to EpCAM-Positive Tumor Cells41
Preparing n-of-1 Antisense Oligonucleotide Treatments for Rare Neurological Diseases in Europe: Genetic, Regulatory, and Ethical Perspectives33
Delivery of RNA Therapeutics: The Great Endosomal Escape!31
Folate Receptor-Mediated siRNA Delivery: Recent Developments and Future Directions for RNAi Therapeutics29
Challenges and Opportunities for Nucleic Acid Therapeutics28
Oligonucleotides and the COVID-19 Pandemic: A Perspective26
High Levels of Apoptosis Are Induced in the Human Colon Cancer HT-29 Cell Line by Co-Administration of Sulforaphane and a Peptide Nucleic Acid Targeting miR-15b-5p25
Non-Small-Cell Lung Cancer Regression by siRNA Delivered Through Exosomes That Display EGFR RNA Aptamer23
Underlying Immune Disorder May Predispose Some Transthyretin Amyloidosis Subjects to Inotersen-Mediated Thrombocytopenia22
Likelihood of Nonspecific Activity of Gapmer Antisense Oligonucleotides Is Associated with Relative Hybridization Free Energy21
Technical Considerations for Use of Oligonucleotide Solution API20
miR-21: A Key Small Molecule with Great Effects in Combination Cancer Therapy19
Delivery of Antisense Oligonucleotides to the Cornea19
Researcher's Perceptions on Publishing “Negative” Results and Open Access19
Acute Neurotoxicity of Antisense Oligonucleotides After Intracerebroventricular Injection Into Mouse Brain Can Be Predicted from Sequence Features19
Mesyl Phosphoramidate Oligonucleotides as Potential Splice-Switching Agents: Impact of Backbone Structure on Activity and Intracellular Localization17
Drug Metabolism and Pharmacokinetics of Antisense Oligonucleotide Therapeutics: Typical Profiles, Evaluation Approaches, and Points to Consider Compared with Small Molecule Drugs16
Metabolic Benefits of MicroRNA-22 Inhibition16
Population Pharmacokinetic–Pharmacodynamic Modeling of Inotersen, an Antisense Oligonucleotide for Treatment of Patients with Hereditary Transthyretin Amyloidosis15
Human Papillomavirus G-Rich Regions as Potential Antiviral Drug Targets15
Immunogenicity Assessment of Inotersen, a 2′-O-(2-Methoxyethyl) Antisense Oligonucleotide in Animals and Humans: Effect on Pharmacokinetics, Pharmacodynamics, and Safety14
Antisense Oligonucleotides as Potential Therapeutics for Type 2 Diabetes14
Pyrene-Modified DNA Aptamers with High Affinity to Wild-Type EGFR and EGFRvIII13
Population Pharmacokinetic–Pharmacodynamic Model of Serum Transthyretin Following Patisiran Administration13
Effects of Chemical Modifications on siRNA Strand Selection in Mammalian Cells12
Assay, Purity, and Impurity Profile of Phosphorothioate Oligonucleotide Therapeutics by Ion Pair–HPLC–MS12
Anti-CD44 DNA Aptamers Selectively Target Cancer Cells12
Quantification of Antisense Oligonucleotides by Splint Ligation and Quantitative Polymerase Chain Reaction12
Modification of KL4 Peptide Revealed the Importance of Alpha-Helical Structure for Efficient siRNA Delivery11
Impact of Serum Proteins on the Uptake and RNAi Activity of GalNAc-Conjugated siRNAs11
Interspecies Scaling of Human Clearance and Plasma Trough Exposure for Antisense Oligonucleotides: A Retrospective Analysis of GalNAc3-Conjugated and Unconjugated-Antisense Oligonucleotides11
Considerations in the Preclinical Assessment of the Safety of Antisense Oligonucleotides11
The Performance of Minicircle DNA Versus Parental Plasmid in p53 Gene Delivery Into HPV-18-Infected Cervical Cancer Cells11
Pharmacodynamic and Pharmacokinetic Properties of Full Phosphorothioate Small Interfering RNAs for Gene Silencing In Vivo10
Evaluation of Phosphorus and Non-Phosphorus Neutral Oligonucleotide Backbones for Enhancing Therapeutic Index of Gapmer Antisense Oligonucleotides10
Knockdown of Muscle-Specific Ribosomal Protein L3-Like Enhances Muscle Function in Healthy and Dystrophic Mice10
The Combination of Mesyl-Phosphoramidate Inter-Nucleotide Linkages and 2′-O-Methyl in Selected Positions in the Antisense Oligonucleotide Enhances the Performance of RNaseH1 Active PS-ASOs10
Perspectives on the Designation of Oligonucleotide Starting Materials10
Modulation of RNA Splicing by Oligonucleotides: Mechanisms of Action and Therapeutic Implications10
RT-qPCR Methods to Support Pharmacokinetics and Drug Mechanism of Action to Advance Development of RNAi Therapeutics10
Solid-Phase Separation of Toxic Phosphorothioate Antisense Oligonucleotide-Protein Nucleolar Aggregates Is Cytoprotective10
0.02173900604248